X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs CADILA HEALTHCARE - Comparison Results

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES CADILA HEALTHCARE VENUS REMEDIES/
CADILA HEALTHCARE
 
P/E (TTM) x -9.7 23.7 - View Chart
P/BV x 0.2 5.9 2.5% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 VENUS REMEDIES   CADILA HEALTHCARE
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-17
CADILA HEALTHCARE
Mar-17
VENUS REMEDIES/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs143460 31.0%   
Low Rs65305 21.3%   
Sales per share (Unadj.) Rs324.292.1 352.0%  
Earnings per share (Unadj.) Rs6.414.8 43.3%  
Cash flow per share (Unadj.) Rs40.618.5 219.6%  
Dividends per share (Unadj.) Rs03.20 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs366.068.0 538.3%  
Shares outstanding (eoy) m12.341,023.74 1.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.34.2 7.7%   
Avg P/E ratio x16.225.8 62.8%  
P/CF ratio (eoy) x2.620.7 12.4%  
Price / Book Value ratio x0.35.6 5.0%  
Dividend payout %021.6 0.0%   
Avg Mkt Cap Rs m1,282391,581 0.3%   
No. of employees `0000.916.9 5.4%   
Total wages/salary Rs m25115,002 1.7%   
Avg. sales/employee Rs Th4,430.15,594.5 79.2%   
Avg. wages/employee Rs Th278.0890.1 31.2%   
Avg. net profit/employee Rs Th87.6899.9 9.7%   
INCOME DATA
Net Sales Rs m4,00094,295 4.2%  
Other income Rs m231,286 1.8%   
Total revenues Rs m4,02395,581 4.2%   
Gross profit Rs m78519,036 4.1%  
Depreciation Rs m4223,750 11.2%   
Interest Rs m344450 76.4%   
Profit before tax Rs m4216,122 0.3%   
Minority Interest Rs m0338 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3 0.0%   
Tax Rs m-371,289 -2.9%   
Profit after tax Rs m7915,168 0.5%  
Gross profit margin %19.620.2 97.2%  
Effective tax rate %-87.98.0 -1,099.2%   
Net profit margin %2.016.1 12.3%  
BALANCE SHEET DATA
Current assets Rs m2,60660,223 4.3%   
Current liabilities Rs m1,98053,058 3.7%   
Net working cap to sales %15.67.6 205.9%  
Current ratio x1.31.1 115.9%  
Inventory Days Days12870 183.7%  
Debtors Days Days4388 48.9%  
Net fixed assets Rs m5,35372,984 7.3%   
Share capital Rs m1231,024 12.1%   
"Free" reserves Rs m4,39368,576 6.4%   
Net worth Rs m4,51669,600 6.5%   
Long term debt Rs m1,61824,684 6.6%   
Total assets Rs m8,291152,207 5.4%  
Interest coverage x1.136.8 3.0%   
Debt to equity ratio x0.40.4 101.0%  
Sales to assets ratio x0.50.6 77.9%   
Return on assets %5.110.3 49.7%  
Return on equity %1.821.8 8.0%  
Return on capital %6.317.9 35.1%  
Exports to sales %00-   
Imports to sales %18.40-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m736NA-   
Fx inflow Rs m021,280 0.0%   
Fx outflow Rs m73610,874 6.8%   
Net fx Rs m-73610,406 -7.1%   
CASH FLOW
From Operations Rs m99713,495 7.4%  
From Investments Rs m-461-29,103 1.6%  
From Financial Activity Rs m-57123,158 -2.5%  
Net Cashflow Rs m-357,556 -0.5%  

Share Holding

Indian Promoters % 32.9 74.8 43.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 8.3 2.2%  
FIIs % 0.6 5.9 9.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 11.0 603.6%  
Shareholders   20,121 44,069 45.7%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   ALEMBIC LTD  SHASUN PHARMA  PFIZER  FDC LTD.  SUN PHARMA  

Compare VENUS REMEDIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens 99 Points Down; Vedanta & Coal India Top Losers(09:30 am)

Asian share markets are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 0.9% while the Hang Seng is down 2%. The Shanghai Composite is trading down by 2.7%.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2%

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY18); Net Profit Up 50.4%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, CADILA HEALTHCARE has posted a net profit of Rs 6 bn (up 50.4% YoY). Sales on the other hand came in at Rs 33 bn (up 28.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Jun 19, 2018 10:35 AM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS